Last reviewed · How we verify
NCT02585401
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
trial testing Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) in Age-related Macular Degeneration (AMD) in 99 participants. Completed in 19 May 2016.
31 March 2016
Quick facts
| Lead sponsor | Bayer |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 99 |
| Start date | 18 February 2016 |
| Primary completion | 31 March 2016 |
| Estimated completion | 19 May 2016 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) — full drug profile →
Conditions studied
- Age-related Macular Degeneration (AMD) — all drugs for Age-related Macular Degeneration (AMD) →
- Central Retinal Vein Occlusion (CRVO) — all drugs for Central Retinal Vein Occlusion (CRVO) →
- Diabetic Macular Edema (DME) — all drugs for Diabetic Macular Edema (DME) →
Sponsor
Bayer — full company profile →
Who can join
Eligibility, any sex, with Age-related Macular Degeneration (AMD) or Central Retinal Vein Occlusion (CRVO). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02585401
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Trials testing the same drug.
- NCT03521895 — An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based · completed
- NCT03470103 — A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use o · completed
- NCT03411941 — Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neova · completed
- NCT02850263 — A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema · completed
- NCT02581995 — Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label · Phase 4 · completed
Other recruiting trials for Age-related Macular Degeneration (AMD)
Currently open trials in the same condition.
- NCT06541704 — A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult · Phase 3 · recruiting
- NCT07084883 — Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneratio · recruiting
- NCT04292080 — Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy · Phase 2 · recruiting
Other Bayer trials
Trials by the same sponsor.
- NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
- NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
- NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02585401 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bayer
- Last refreshed: 21 March 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02585401.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing